NLRP3 inflammasome as a novel player in myocardial infarction

International Heart Journal

Volumn 55, Issue 2, 2014, Pages 101-105

  Takahashi, Masafumi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytokine; Inflammation; Interleukin; Reperfusion

Indexed keywords

ADENOSINE TRIPHOSPHATE; CANAKINUMAB; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CRYOPYRIN; GAMMA INTERFERON; GEVOKIZUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; IRARIS; LECTIN RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PURINERGIC P2X7 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOIC ACID INDUCIBLE PROTEIN I; RILONACEPT; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CLINICAL TRIAL (TOPIC); HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART RUPTURE; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; CARRIER PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; MACROPHAGES; MYOCARDIAL INFARCTION;

EID: 84897034479     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-388     Document Type: Article

References (41)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35. (Review)
2. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47. (Review)
3. Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 2010; 74: 418-23. (Review)
4. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-37.
5. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65. (Review)
6. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-35. (Review)
7. Strowig T, Henao-Mejia J, Elinav E, et al. Inflammasomes in health and disease. Nature 2012; 481: 278-86. (Review)
8. Usui F, Shirasuna K, Kimura H, et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-defi cient mice. Biochem Biophys Res Commun 2012; 425: 162-8.
9. Yajima N, Takahashi M, Morimoto H, et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation 2008; 117: 3079-87.
10. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/ reperfusion injury. Circulation 2011; 123: 594-604.
11. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-20. (Review)
12. Feng Y, Chao W. Toll-like receptors and myocardial inflammation. Int J Inflam 2011; 2011: 170-352.
13. Takahashi M. Role of the inflammasome in myocardial infarction. Trends Cardiovasc Med 2011; 21: 37-41. (Review)
14. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444-54. (Review)
15. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108: 1133-45. (Review)
16. Takahashi M. Role of innate immune system in inflammation and cardiac remodeling after myocardial infarction. Curr Vasc Pharmacol 2013. (in press)
17. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflam masomes. Nat Rev Immunol 2013; 13: 397-411. (Review)
18. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-32.
19. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
20. Pazár B, Ea HK, Narayan S, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immunol 2011; 186: 2495-502.
21. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-61.
22. Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010; 5: e11765.
23. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857-65.
24. Yamasaki K, Muto J, Taylor KR, et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 2009; 284: 12762-71.
25. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
26. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-7.
27. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res 2012; 110: 126-44. (Review)
28. Hwang MW, Matsumori A, Furukawa Y, et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001; 38: 1546-53.
29. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117: 2670-83.
30. Porter KE, Turner NA. Cardiac fi broblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-78. (Review)
31. Souders CA, Bowers SL, Baudino TA. Cardiac fi broblast: the renaissance cell. Circ Res 2009; 105: 1164-76. (Review)
32. Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 2011; 108: 19725- 30.
33. Sandanger Ø, Ranheim T, Vinge LE, et al. The NLRP3 inflammasome is up-regulated in cardiac fi broblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res 2013; 99: 164- 74.
34. Shigeoka AA, Mueller JL, Kambo A, et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemiareperfusion injury. J Immunol 2010; 185: 6277-85.
35. Inoue Y, Yasuda Y, Takahashi M. Role of the inflammasome in inflammatory responses and subsequent injury after hepatic ischemia-reperfusion injury. Hepatology 2013; 58: 2212.
36. Zuurbier CJ, Jong WM, Eerbeek O, et al. Deletion of the innate immune NLRP3 receptor abolishes cardiac ischemic preconditioning and is associated with decreased Il-6/STAT3 signaling. PLoS One 2012; 7: e40643.
37. Jong WM, Zuurbier CJ. A role for NLRP3 inflammasome in acute myocardial ischaemia-reperfusion injury? Cardiovasc Res 2013; 99: 226.
38. Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin- 1 in heart disease. Circulation 2013; 128: 1910-23. (Review)
39. Abbate A, Van Tassell BW, Seropian IM, et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 2010; 12: 319-22.
40. Toldo S, Mezzaroma E, Van Tassell BW, et al. Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol 2013; 98: 734-45.
41. Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking interleukin- 1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs 2012; 26: 217-33. (Review)